The final outcome of the rights issue entailed a capital injection of SEK 39.2 million before issue costs and repayment of the bridge loan.

"Since we are waiting for customer orders of larger volumes, this capital injection was necessary to lead and complete our new and ongoing customer projects, bringing them to final product," said Daniel Vallin, CEO of Cell Impact.

Cell Impact operates in a challenging market. There are well-known geopolitical reasons behind this, but the market itself - in terms of customers, suppliers and technology - is also still under development.

"I am pleased, but also humbled, to say that we have continuously been able to strengthen our position by broadening our customer base and reducing our dependence on individual customers," concluded Daniel Vallin.

Financial summary

• Net sales totaled SEK 2.1 million (23.8).
• Operating loss (EBIT) was SEK -20.0 million (-19.6).
• The Group's result after financial items was SEK -21.2 million (-20.9).
• Earnings per share attributable to the Parent Company's shareholders before and after dilution totaled SEK -0.03 (-0.04).
• Debt/equity ratio was 78 percent (82) on the balance sheet date.
• Cash flows from operating activities amounted to SEK -11.9 million (-19.3).
• On the balance sheet date, the Group's cash and cash equivalents totaled SEK 1 million (22.6). As of August 21, the cash balance amounted to SEK 16.1 million.

This information is inside information that Cell Impact AB is obliged to make public pursuant to the EU Market Abuse Regulation.